NAD Augmentation to Treat Diabetes Kidney Disease: A Randomized Controlled Trial
A phase 2a trial randomized, double-blind, placebo-controlled, parallel group trial to determine whether NMN administration improves DKD, as indicated by a significantly greater reduction in UACR compared with placebo administration. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily.
• Has T2DM, as indicated by any of the following:
‣ Self-report of diabetes plus the use of a prescribed diabetes medication.
⁃ ICD-10 code for diabetes plus current use of a diabetes medication in the electronic medical record.
⁃ HbA1c \>6.4%; or 2 fasting glucose \> 125 mg/dL
• Fasting morning UACR between 100 and 2,000 mg/g creatinine on two separate days
• If UACR is \> 300 mg/g creatinine, must be currently using an ACE inhibitor or an ARB
• eGFR \> 30 mL/ min / 1.73 m2
• Hemoglobin A1c \<9%
• Able to speak English or Spanish
• Willing and able to provide written informed consent
• In addition, female participants must Not be pregnant and not planning to become pregnant over the next 6 months